Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 4/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | UGCG | Q16739 | 2/20 | 0.41 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19608820 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHRNAAAHRH4 | |
| SCHEMBL1422059 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHRNAAAHRH4 | |
| SCHEMBL23014897 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHRNAAAHRH4 | |
| SCHEMBL3376445 | 0.98 | TSHR (0.50) | L3MBTL1TDP1TSHRNAAAHRH4 | |
| SCHEMBL1603273 | 0.93 | TSHR (0.52) | L3MBTL1TDP1TSHRNAAAHRH4 | |
| SCHEMBL23567326 | 0.92 | TSHR (0.44) | L3MBTL1TDP1TSHRNAAAHRH4 | |
| SCHEMBL23567282 | 0.92 | TSHR (0.44) | L3MBTL1TDP1TSHRNAAAHRH4 | |
| SCHEMBL23567301 | 0.92 | TSHR (0.44) | L3MBTL1TDP1TSHRNAAAHRH4 | |
| SCHEMBL23567238 | 0.92 | TSHR (0.44) | L3MBTL1TDP1TSHRNAAAHRH4 | |
| SCHEMBL23567217 | 0.92 | TSHR (0.44) | L3MBTL1TDP1TSHRNAAAHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144194-A1 | CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | AXOGLIA THERAPEUTICS (LU) | 2011-06-16 | — | — | US | disclosed |
| EP-2297127-A1 | CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | AxoGlia Therapeutics S.A. (LU) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009130253-A1 | CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | AXOGLIA THERAPEUTICS S.A. (LU) | 2009-10-29 | — | — | WO | disclosed |
| EP-2112145-A1 | Chromenone derivatives useful for the treatment of neurodegenerative diseases | AxoGlia Therapeutics S.A. (LU) | 2009-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144194-A1 | CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PARK7, CDR2, SNCA | L3MBTL1 1440/4885TDP1 575/4885TSHR 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.